SteroTherapeutics is pursuing a novel drug therapy for major diseases related to metabolic syndrome, which afflicts 35% of the US adult population. Cushing's syndrome is caused by elevated levels of a hormone called cortisol, which can promote obesity, diabetes, hypertension, cardiovascular disease, and immune dysfunction. Cushing's, which is an orphan disease, is poorly served by currently available therapies that only modestly effective and have substantial side effects. SteroTherapeutics recently signed the CRADA agreement with NIH to develop a novel treatment for Cushing syndrome patients.
The company is also developing a treatment for Non-alcoholic Steatohepatitis (NASH) which has been predicted as the next major health epidemic. The situation is paramount as NASH has no approved treatments and is a leading cause of liver-related morbidity and mortality. Analysts are forecasting that the market for NASH treatment could reach $35-$40 Billion by 2025.
For any inquiries or questions please call: 267-300-0010 or fill out the following form
3805 Old Easton Rd
Doylestown, PA 18902